27-Feb-2026
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
Globe Newswire (Wed, 25-Feb 7:00 AM ET)
EyePoint Announces Participation at Upcoming Investor Conferences
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities
TipRanks (Tue, 24-Feb 6:56 AM ET)
EyePoint Appoints Michael Campbell as Chief Commercial Officer
Globe Newswire (Wed, 18-Feb 7:00 AM ET)
EyePoint’s Inducement Options Grant Signals Confidence Amid Advancing Retinal Drug Pipeline
Market Chameleon (Tue, 17-Feb 5:31 AM ET)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Tue, 17-Feb 7:00 AM ET)
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Thu, 5-Feb 7:00 AM ET)
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
Globe Newswire (Wed, 7-Jan 7:00 AM ET)
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 17-Dec 7:00 AM ET)
EyePoint Extends Cash Runway to Q4 2027 as Phase 3 DURAVYU Trials Accelerate for Wet AMD and DME
Market Chameleon (Wed, 5-Nov 4:39 AM ET)
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Eyepoint trades on the NASDAQ stock market under the symbol EYPT.
As of February 27, 2026, EYPT stock price declined to $17.56 with 2,322,332 million shares trading.
EYPT has a beta of 2.18, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.24 to the broad based SPY ETF.
EYPT has a market cap of $1.42 billion. This is considered a Small Cap stock.
Last quarter Eyepoint reported $966,000 in Revenue and -$.85 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.08.
In the last 3 years, EYPT traded as high as $30.99 and as low as $2.21.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, IWM, IWN, VXF, SCHA.
EYPT has outperformed the market in the last year with a price return of +197.6% while the SPY ETF gained +16.6%. EYPT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.7% and +35.0%, respectively, while the SPY returned +1.2% and +0.7%, respectively.
EYPT support price is $16.87 and resistance is $18.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.